Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Neuromuscular Disorders Channel:
Myasthenia Gravis

Welcome to The Myasthenia Gravis Channel

VJNeurology brings you the latest updates in myasthenia gravis directly from world-leading experts. The Myasthenia Gravis Channel brings you video interviews from international conferences.

Discover key developments in this space, including updates in disease biology, novel treatment strategies, and ongoing clinical trials.

Sustained disease control with nipocalimab in gMG: post-hoc analysis of Vivacity-MG3 4:33
Sustained disease control with nipocalimab in gMG: post-hoc analysis of Vivacity-MG3
Richard Nowak • 28 Jun 2026
Adverse events of special interest during the RCP: Myasthenia Gravis Inebilizumab Trial 3:58
Adverse events of special interest during the RCP: Myasthenia Gravis Inebilizumab Trial
Richard Nowak • 24 Jun 2026
One big question with Richard Nowak: what MG advance could transform care in the next 3 years? 2:07
One big question with Richard Nowak: what MG advance could transform care in the next 3 years?
Richard Nowak • 28 Jun 2026
The evolving treatment landscape for myasthenia gravis and emerging approaches on the horizon 4:03
The evolving treatment landscape for myasthenia gravis and emerging approaches on the horizon
Richard Nowak • 27 Jun 2026
Safety and efficacy of miv-cel in autoimmune neuromuscular conditions 1:47
Safety and efficacy of miv-cel in autoimmune neuromuscular conditions
Jeremias Motte • 26 Apr 2026
CAR T-cell therapy in myasthenia gravis: advances and future perspectives 6:37
CAR T-cell therapy in myasthenia gravis: advances and future perspectives
Ali Habib • 12 Apr 2025
Myasthenia gravis inebilizumab trial (MINT): efficacy and safety in patients with generalized MG 5:42
Myasthenia gravis inebilizumab trial (MINT): efficacy and safety in patients with generalized MG
Richard Nowak • 6 Apr 2025
What should be done in pregnancy for pts with myasthenia gravis & unanswered questions that remain 1:22
What should be done in pregnancy for pts with myasthenia gravis & unanswered questions that remain
Jenny Lindroos • 2 Jul 2024
Improving the assessment of patients with MG: monitoring QoL & psychiatric comorbidities 2:35
Improving the assessment of patients with MG: monitoring QoL & psychiatric comorbidities
Francesco Sacca • 1 Jul 2024
Neuromuscular disorder treatment updates at EAN 2024 1:00
Neuromuscular disorder treatment updates at EAN 2024
Nicolas Dubuisson • 2 Jul 2024
Real-world data reporting in myasthenia gravis 0:53
Real-world data reporting in myasthenia gravis
Francesco Sacca • 1 Jul 2024
Treating myasthenia gravis in pregnancy 2:00
Treating myasthenia gravis in pregnancy
Jenny Lindroos • 2 Jul 2024
How to treat myasthenic crisis 1:29
How to treat myasthenic crisis
Francesco Sacca • 1 Jul 2024
Real-world comparison of eculizumab and efgartigimod for generalized myasthenia gravis 3:05
Real-world comparison of eculizumab and efgartigimod for generalized myasthenia gravis
Francesco Sacca • 1 Jul 2024
Transient neonatal myasthenia gravis: detection and treatment 3:10
Transient neonatal myasthenia gravis: detection and treatment
Jenny Lindroos • 2 Jul 2024
Why are newer treatments not used first line in myasthenia gravis? 0:55
Why are newer treatments not used first line in myasthenia gravis?
Francesco Sacca • 1 Jul 2024

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJNeurology is intended for healthcare professionals